Shots:

• The P-III THALES study involves assessing of Brilinta (90mg- bid) + aspirin vs aspirin as monothx. in 11-000+ patients with minor acute ischemic stroke or high-risk TIA in the 24hrs. prior to treatment initiation
• The P-III THALES study resulted in a reduction in risk of stroke and death after an acute ischemic stroke or TIA- improved outcomes- the reduction in risk of devastating events- safety is consistent with the known profile along with an increment in bleeding rate
• Brilinta is a reversible- direct-acting P2Y12 receptor antagonist acts by inhibiting platelet activation- co-administered with aspirin to prevent atherothrombotic events in adult patients with ACS or MI

Click here ­to­ read full press release/ article

Ref: AstraZeneca  | Image: AstraZeneca